Katherine Collins, Associate, Patent Attorney (Life Sciences) at IP firm Mewburn Ellis
25 April 2024NewsBiotechnologyKatherine Collins

Meeting the cell and gene therapy scale-up challenge

Improving patient access is a UN goal but for companies transitioning from trials to full-scale production, IP is essential, explains Katherine Collins of Mewburn Ellis.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Biotechnology
26 June 2026   Deal is aimed at strengthening German company’s presence across high-growth life sciences markets by adding a portfolio of advanced research and analytical technologies.
Biotechnology
25 June 2026   Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines.
Biotechnology
22 June 2026   The partnership, announced at BIO 2026, marks the largest Asia-Pacific partnership by potential value that the AI-driven drug discovery company has secured to date.